Sunday 05 April 2020 - 06:08
In Business 40 Years - Since 1980
Online ordering via the shopping cart is working again on our web site! We have solved the technical issues on our servers and want to assure our valuable customers that the updates made will ensure that your personal and credit card information continue to remain secure. We apologize for any difficulties you may have encountered during this time.
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
N-5688 Niraparib, p-Toluenesulfonate Salt, >99%
Synonyms : [MK-4827]
Related Terms : [Zejula]
- Size
- US $
- €
- £
- ¥
- 1 mg
- 48
- 44
- 39
- 5,200
- In stock
- 5 mg
- 59
- 54
- 48
- 6,400
- In stock
- 10 mg
- 78
- 72
- 63
- 8,500
- In stock
- 25 mg
- 106
- 98
- 86
- 11,500
- In stock
- 50 mg
- 133
- 123
- 108
- 14,400
- In stock
- 100 mg
- 199
- 184
- 162
- 21,600
- In stock
- 200 mg
- 334
- 308
- 272
- 36,200
- In stock
- 500 mg
- 662
- 612
- 539
- 71,800
- In stock
- 1 g
- 970
- 897
- 790
- 105,200
- In stock
- 2 g
- 1,570
- 1,452
- 1,279
- 170,200
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 492.59
- C19H20N4O•C7H8O3S
- [1038915-73-9]
Solubility: DMSO.
- Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells. In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities. Mueller S., et al. "Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma." Anticancer Res. 33: 755-762 (2013).
- A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day. Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. Sandhu S.K., et al. "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncol. 14: 882-892 (2013).
- Related CAS numbers: 1038915-64-8 for the hydrochloride salt; 1038915-60-4 for the free base; 1171196-88-5 for the sulfate salt.
- Niraparib Tosylate monohydrate is the active ingredient in the drug sold under the trade name Zejula®. This drug has been approved in at least one country for use in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. NOTE: THE NIRAPARIB TOSYLATE MONOHYDRATE SOLD BY THE LC LABORATORIES IS NOT ZEJULA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
